{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:40:52Z","timestamp":1791474052778,"version":"4.3.4"},"reference-count":33,"publisher":"American Diabetes Association","issue":"8","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>GLP-1 receptor agonists may provide an alternative to prandial insulin for advancing basal insulin therapy. Harmony 6 was a randomized, open-label, active-controlled trial testing once-weekly albiglutide vs. thrice-daily prandial insulin lispro as an add-on to titrated once-daily insulin glargine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Patients taking basal insulin (with or without oral agents) with HbA1c 7\u201310.5% (53\u201391 mmol\/mol) entered a glargine standardization period, followed by randomization to albiglutide, 30 mg weekly (n = 282), subsequently uptitrated to 50 mg, if necessary, or thrice-daily prandial lispro (n = 281) while continuing metformin and\/or pioglitazone. Glargine was titrated to fasting plasma glucose of &amp;lt;5.6 mmol\/L, and lispro was adjusted based on glucose monitoring. The primary end point was the difference in the HbA1c change from baseline at week 26.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>At week 26, HbA1c decreased from baseline by \u22120.82 \u00b1 SE 0.06% (9.0 mmol\/mol) with albiglutide and \u22120.66 \u00b1 0.06% (7.2 mmol\/mol) with lispro; treatment difference, \u22120.16% (95% CI \u22120.32 to 0.00; 1.8 mmol\/mol; P &amp;lt; 0.0001), meeting the noninferiority end point (margin, 0.4%). Weight decreased with albiglutide but increased with lispro (\u22120.73 \u00b1 0.19 kg vs. +0.81 \u00b1 0.19 kg). The mean glargine dose increased from 47 to 53 IU (albiglutide) and from 44 to 51 IU (lispro). Adverse events for albiglutide versus lispro included severe hypoglycemia (0 vs. 2 events), documented symptomatic hypoglycemia (15.8% vs. 29.9%), nausea (11.2% vs. 1.4%), vomiting (6.7% vs. 1.4%), and injection site reactions (9.5% vs. 5.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Weekly albiglutide is a simpler therapeutic option than thrice-daily lispro for advancing basal insulin glargine therapy, resulting in comparable HbA1c reduction with weight loss and lower hypoglycemia risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc14-0001","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T23:58:29Z","timestamp":1401926309000},"page":"2317-2325","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":185,"title":["Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro"],"prefix":"10.2337","volume":"37","author":[{"given":"Julio","family":"Rosenstock","sequence":"first","affiliation":[{"name":"Dallas Diabetes and Endocrine Center, Medical City Dallas Hospital, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian A.","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Tulane University Health Sciences Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Gross","sequence":"additional","affiliation":[{"name":"Endocrine Division, Hospital de Cl\u00ednicas de Porto Alegre and Universidade Federal do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Ratner","sequence":"additional","affiliation":[{"name":"Medstar Health Research Institute, Hyattsville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ahr\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis C.C.","family":"Chow","sequence":"additional","affiliation":[{"name":"The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Yang","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Merion, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Miller","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Merion, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray W.","family":"Stewart","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Merion, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"Keenan Research Center, Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital, and Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,7,12]]},"reference":[{"key":"2022031220055551000_B1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/DMSO.S14653","article-title":"Insulin initiation and intensification in patients with T2DM for the primary care physician","volume":"4","author":"Unger","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022031220055551000_B2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","article-title":"A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"51","author":"Rosenstock","year":"2008","journal-title":"Diabetologia"},{"key":"2022031220055551000_B3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dc07-1122","article-title":"Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension\/lispro) versus basal\/bolus (glargine\/lispro) therapy","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031220055551000_B4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12325-010-0020-y","article-title":"Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes","volume":"27","author":"Heintjes","year":"2010","journal-title":"Adv Ther"},{"key":"2022031220055551000_B5","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031220055551000_B6","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1089\/dia.2011.0001","article-title":"Basal plus basal-bolus approach in type 2 diabetes","volume":"13","author":"Ampudia-Blasco","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"2022031220055551000_B7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.diabres.2007.09.013","article-title":"Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies","volume":"79","author":"Davies","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031220055551000_B8","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031220055551000_B9","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4158\/EP.14.6.750","article-title":"Hypoglycemia: still the limiting factor in the glycemic management of diabetes","volume":"14","author":"Cryer","year":"2008","journal-title":"Endocr Pract"},{"key":"2022031220055551000_B10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-154-10-201105170-00007","article-title":"Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis","volume":"154","author":"Gross","year":"2011","journal-title":"Ann Intern Med"},{"key":"2022031220055551000_B11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"2022031220055551000_B12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/DDDT.S10180","article-title":"Liraglutide in the management of type 2 diabetes","volume":"4","author":"Wajcberg","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"2022031220055551000_B13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1517\/14656560802611832","article-title":"Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus","volume":"10","author":"Wajcberg","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"2022031220055551000_B14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"2022031220055551000_B15","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcd.2011.09.002","article-title":"Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction","author":"Lind","year":"2012","journal-title":"Prim Care Diabetes"},{"key":"2022031220055551000_B16","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc11-1928","article-title":"Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets","volume":"35","author":"DeVries","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031220055551000_B17","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031220055551000_B18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jdiacomp.2013.04.008","article-title":"One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target","volume":"27","author":"Rosenstock","year":"2013","journal-title":"J Diabetes Complications"},{"key":"2022031220055551000_B19","doi-asserted-by":"crossref","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly GLP-1 receptor agonists - available efficacy and safety data and perspectives for the future","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031220055551000_B20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1358\/dof.2010.035.09.1516042","article-title":"Albiglutide.","volume":"35","author":"Rosenstock","year":"2010","journal-title":"Drugs Future"},{"key":"2022031220055551000_B21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects","volume":"11","author":"Bush","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2022031220055551000_B22","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.2337\/dc09-0366","article-title":"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing","volume":"32","author":"Rosenstock","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031220055551000_B23","first-page":"579","article-title":"Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes","volume":"11","author":"Tomkin","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"2022031220055551000_B24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","article-title":"Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia","volume":"28","author":"Workgroup on Hypoglycemia, American Diabetes Association","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031220055551000_B25","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"2022031220055551000_B26"},{"key":"2022031220055551000_B27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"2022031220055551000_B28","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":"DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031220055551000_B29"},{"key":"2022031220055551000_B30","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/dmrr.989","article-title":"Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes","volume":"25","author":"Raskin","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031220055551000_B31","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.diabres.2011.10.021","article-title":"An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study","volume":"94","author":"Home","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031220055551000_B32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1463-1326.2009.01165.x","article-title":"Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study","volume":"12","author":"Fritsche","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2022031220055551000_B33","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1185\/03007995.2013.803053","article-title":"Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study","volume":"29","author":"Oguz","year":"2013","journal-title":"Curr Med Res Opin"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/8\/2317\/621448\/2317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/8\/2317\/621448\/2317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T16:53:43Z","timestamp":1647104023000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/37\/8\/2317\/29571\/Advancing-Basal-Insulin-Replacement-in-Type-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,12]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,7,12]]},"published-print":{"date-parts":[[2014,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc14-0001","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,12]]}}}